Long-Term Follow-Up (LTFU) Monitoring & Analysis
Long-Term Follow-Up (LTFU) Monitoring & Analysis
Integrating vectors (lentivirus, γ-retrovirus, transposons) and genome editing products write exogenous genetic material permanently into the host genome — the very source of their therapeutic durability, and equally the source of delayed safety risk. Insertional mutagenesis may not manifest until months or years after dosing, when a previously inconspicuous clone gains a proliferative advantage and expands toward malignant transformation — a risk sobering by the historical SCID-X1 cases driven by integration near the LMO2 locus. The FDA guidance on Long-Term Follow-Up After Administration of Human Gene Therapy Products (2020) accordingly requires follow-up of up to 15 years for integrating vectors, transposon systems and genome-edited products, including monitoring of vector persistence and — where feasible — integration site analysis and clonal expansion assessment, with the Pharmacovigilance Plan (PVP) submitted alongside the BLA. Routine clinical visits and standard blood work cannot detect genome-level clonal evolution; longitudinal molecular monitoring is the only reliable means of capturing such delayed events.
ZhuHai GeneRulor's LTFU Monitoring service applies our integration-site characterization platform longitudinally across multi-timepoint follow-up sampling, delivering three tightly integrated analytical capabilities: longitudinal integration site analysis (ISA) based on PacBio HiFi targeted capture, with all timepoints aligned to a unified coordinate system; clonal expansion and dominant-clone assessment derived from abundance distributions (Shannon diversity, unique integration site counts, dominant-clone trajectories, and flagging of high-concern integrations near proto-oncogenes); and quantitative vector persistence and VCN monitoring by qPCR / ddPCR and sequencing. In combination with our integration site verification, single-cell TCR/BCR immune repertoire sequencing, and TCR/BCR multiplex PCR and 5'RACE full-length sequencing, the service builds a multi-dimensional longitudinal evidence chain across integration, clonality and immune repertoire. Deliverables include per-timepoint integration site profiles with longitudinal comparison tables, clonal diversity metrics with expansion alerts, vector persistence / clearance curves over time, and consolidated longitudinal reports formatted for direct inclusion in LTFU data packages and PVPs. All work is performed under GMP-aligned operations with ISO 9001 / CNAS / CAP accreditation, supporting NMPA IND/BLA submissions and globally aligned regulatory engagement.
